An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer-Reference-Cited by-同舟云学术

An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer

Published:2017-07-17 Issue:8 Volume:23 Page:929-937
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Xue Yaohua,Martelotto Luciano,Baslan Timour,Vides Alberto,Solomon Martha,Mai Trang Thi,Chaudhary Neelam,Riely Greg J,Li Bob T,Scott Kerry,Cechhi Fabiola,Stierner Ulrika,Chadalavada Kalyani,de Stanchina Elisa,Schwartz Sarit,Hembrough Todd,Nanjangud Gouri^ORCID,Berger Michael F,Nilsson Jonas,Lowe Scott W,Reis-Filho Jorge S,Rosen Neal,Lito Piro

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.4369.pdf

Reference48 articles.

1. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543–550 (2014).

2. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).

3. Flaherty, K.T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010).

4. Planchard, D. et al. Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicenter, open-label, phase 2 trial. Lancet Oncol. 17, 642–650 (2016).

5. Flaherty, K.T. et al. Combined BRAF and MEK inhibition in melanoma with BRAFV600 mutations. N. Engl. J. Med. 367, 1694–1703 (2012).

Cited by 140 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting calciumopathy for neuroprotection: focus on calcium channels Cav1, Orai1 and P2X7;Cell Calcium;2024-11

2. Role of mitochondria and potential of mitochondria-targeted therapy in BRAF mutant cancer: A review;Critical Reviews in Oncology/Hematology;2024-11

3. FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies;Cancer Communications;2024-08-19

4. In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma;Cell Reports Medicine;2024-08

5. Leveraging Cancer Phenotypic Plasticity for Novel Treatment Strategies;Journal of Clinical Medicine;2024-06-05